K36 Therapeutics
Targets epigenetic pathways to develop innovative cancer therapies.
Targets epigenetic pathways to develop innovative cancer therapies.
Sector
Life SciencesCategory
TherapeuticsLocation
Cambridge, MAInitial Investment
2021K36 Therapeutics was established with the mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies. Its vision is to create breakthrough therapies for the unmet medical needs of cancer patients worldwide.
